Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2011 1
2014 1
2016 2
2017 4
2018 3
2019 6
2020 3
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
Al-Samkari H, Kasthuri RS, Parambil JG, Albitar HA, Almodallal YA, Vázquez C, Serra MM, Dupuis-Girod S, Wilsen CB, McWilliams JP, Fountain EH, Gossage JR, Weiss CR, Latif MA, Issachar A, Mei-Zahav M, Meek ME, Conrad M, Rodriguez-Lopez J, Kuter DJ, Iyer VN. Al-Samkari H, et al. Among authors: issachar a. Haematologica. 2021 Aug 1;106(8):2161-2169. doi: 10.3324/haematol.2020.261859. Haematologica. 2021. PMID: 32675221 Free PMC article.
[CHALLENGES IN LIVER TRANSPLANT 2023].
Rabinowich L, Katchman H, Halaila A, Imam A, Issachar A, Braun M. Rabinowich L, et al. Among authors: issachar a. Harefuah. 2023 Nov;162(9):568-574. Harefuah. 2023. PMID: 37965852 Hebrew.
Editorial: targeting aberrant hepatic inflammation for treatment of non-alcoholic steatohepatitis-authors' reply.
Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, Itzhak I, Lev-Cohain N, Bareket-Samish A, Silverman MH, Fishman P. Safadi R, et al. Among authors: issachar a. Aliment Pharmacol Ther. 2022 Feb;55(4):485-486. doi: 10.1111/apt.16762. Aliment Pharmacol Ther. 2022. PMID: 35092054 No abstract available.
Evaluation of a gene expression biomarker to identify operationally tolerant liver transplant recipients: the LITMUS trial.
Chruscinski A, Rojas-Luengas V, Moshkelgosha S, Issachar A, Luo J, Yowanto H, Lilly L, Smith R, Renner E, Zhang J, Epstein M, Grant D, McEvoy CM, Konvalinka A, Humar A, Adeyi O, Fischer S, Volmer FH, Taubert R, Jaeckel E, Juvet S, Selzner N, Levy GA. Chruscinski A, et al. Among authors: issachar a. Clin Exp Immunol. 2022 Jan 28;207(1):123-139. doi: 10.1093/cei/uxab011. Clin Exp Immunol. 2022. PMID: 35020854 Free PMC article. Clinical Trial.
[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study.
Schmilovitz-Weiss H, Boltin D, Groshar D, Domachevsky L, Rosenbaum E, Issa N, Sapoznikov B, Goren I, Issachar A, Cohen-Naftaly M, Weiss A, Gingold-Belfer R, Bernstine H. Schmilovitz-Weiss H, et al. Among authors: issachar a. Dig Liver Dis. 2021 Jun;53(6):753-759. doi: 10.1016/j.dld.2020.11.013. Epub 2020 Dec 1. Dig Liver Dis. 2021. PMID: 33272861
Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
Safadi R, Braun M, Francis A, Milgrom Y, Massarwa M, Hakimian D, Hazou W, Issachar A, Harpaz Z, Farbstein M, Itzhak I, Lev-Cohain N, Bareket-Samish A, Silverman MH, Fishman P. Safadi R, et al. Among authors: issachar a. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1405-1415. doi: 10.1111/apt.16664. Epub 2021 Oct 20. Aliment Pharmacol Ther. 2021. PMID: 34671996 Free PMC article. Clinical Trial.
27 results